Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide

INTRODUCTION: Identification of cancer biomarkers that inform clinical decisions and reduce the use of ineffective therapies is a major goal of precision oncology. An abnormal splice variant of the androgen receptor, AR-V7, was recently found to confer resistance to novel hormonal therapies (abirate...

Full description

Saved in:
Bibliographic Details
Published in:Prostate
Main Authors: Markowski, Mark C., Frick, Kevin D., Eshleman, James R., Luo, Jun, Antonarakis, Emmanuel S.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5735831/
https://ncbi.nlm.nih.gov/pubmed/27404039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23232
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items